Literature DB >> 17044456

Efficacy of cellulose triacetate dialyzer and polysulfone synthetic hemofilter for continuous venovenous hemofiltration in acute renal failure.

Warangkana Pichaiwong1, Asada Leelahavanichkul, Somchai Eiam-ong.   

Abstract

OBJECTIVE: To compare the clearance performances and biocompatibility between the modified cellulose membrane and the standard synthetic membrane in continuous renal replacement therapy (CRRT). MATERIAL AND
METHOD: Seventeen patients with acute renal failure (ARF) were treated with separated continuous veno venous hemofiltration (CVVH) system conducted with the pre-dilution mode. The modified cellulose used was a Sureflux150E (cellulose triacetate) and the standard synthetic membranes used was an AV-400. Blood and replacement flow rate were kept at 100 and 20 mL/min, respectively. Ultrafiltraion rate was 1,200 mL/hr. Samplings of blood and ultrafiltrate were collected at baseline, 2, 8, 16, and 24 hr.
RESULTS: Patients in both methods could similarly tolerate CRRT with only minor complications. Sureflux 150E and AV-400 provided comparable values of sieving coefficients and clearances of small solutes. The albumin loss in ultrafiltrate by Sureflux 150E was greater than AV-400. The values of life span and biocompatability of both hemofilters were not different.
CONCLUSION: Because of the excellent efficacy and the much cheaper cost, the modified cellulose membrane could be an appropriate alternative to standard synthetic membrane in CRRT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17044456

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  2 in total

Review 1.  Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis.

Authors:  Matthew Brain; Elizabeth Winson; Owen Roodenburg; John McNeil
Journal:  BMC Nephrol       Date:  2017-02-20       Impact factor: 2.388

2.  Continuous Renal Replacement Therapy in Critically Ill Children.

Authors:  Demet Demirkol
Journal:  Turk Arch Pediatr       Date:  2022-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.